<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;utm_medium=rss&amp;ff=20240608121202&amp;utm_source=Chrome
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;utm_medium=rss&amp;ff=20240608121202&amp;utm_source=Chrome" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Sat, 08 Jun 2024 16:12:03 +0000</lastbuilddate>
<pubDate>Fri, 07 Jun 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>RNA interference lowers triglyceride levels</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38849676/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240608121202&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Jun 7. doi: 10.1038/s41569-024-01052-8. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38849676/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240608121202&v=2.18.0.post9+e462414">38849676</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01052-8>10.1038/s41569-024-01052-8</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38849676</guid>
<pubDate>Fri, 07 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Gregory B Lim</dc:creator>
<dc:date>2024-06-07</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>RNA interference lowers triglyceride levels</dc:title>
<dc:identifier>pmid:38849676</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01052-8</dc:identifier>
</item>
<item>
<title>Isthmus progenitor cells contribute to homeostatic cellular turnover and support regeneration following intestinal injury</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38848678/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240608121202&amp;v=2.18.0.post9+e462414
      <description>The currently accepted intestinal epithelial cell organization model proposes that Lgr5^(+) crypt-base columnar (CBC) cells represent the sole intestinal stem cell (ISC) compartment. However, previous studies have indicated that Lgr5^(+) cells are dispensable for intestinal regeneration, leading to two major hypotheses: one favoring the presence of a quiescent reserve ISC and the other calling for differentiated cell plasticity. To investigate these possibilities, we studied crypt epithelial...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jun 6;187(12):3056-3071.e17. doi: 10.1016/j.cell.2024.05.004.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The currently accepted intestinal epithelial cell organization model proposes that Lgr5<sup>+</sup> crypt-base columnar (CBC) cells represent the sole intestinal stem cell (ISC) compartment. However, previous studies have indicated that Lgr5<sup>+</sup> cells are dispensable for intestinal regeneration, leading to two major hypotheses: one favoring the presence of a quiescent reserve ISC and the other calling for differentiated cell plasticity. To investigate these possibilities, we studied crypt epithelial cells in an unbiased fashion via high-resolution single-cell profiling. These studies, combined with in vivo lineage tracing, show that Lgr5 is not a specific ISC marker and that stemness potential exists beyond the crypt base and resides in the isthmus region, where undifferentiated cells participate in intestinal homeostasis and regeneration following irradiation (IR) injury. Our results provide an alternative model of intestinal epithelial cell organization, suggesting that stemness potential is not restricted to CBC cells, and neither de-differentiation nor reserve ISC are drivers of intestinal regeneration.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38848678/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240608121202&v=2.18.0.post9+e462414">38848678</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.05.004>10.1016/j.cell.2024.05.004</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38848678</guid>
<pubDate>Fri, 07 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Ermanno Malagola</dc:creator>
<dc:creator>Alessandro Vasciaveo</dc:creator>
<dc:creator>Yosuke Ochiai</dc:creator>
<dc:creator>Woosook Kim</dc:creator>
<dc:creator>Biyun Zheng</dc:creator>
<dc:creator>Luca Zanella</dc:creator>
<dc:creator>Alexander L E Wang</dc:creator>
<dc:creator>Moritz Middelhoff</dc:creator>
<dc:creator>Henrik Nienhüser</dc:creator>
<dc:creator>Lu Deng</dc:creator>
<dc:creator>Feijing Wu</dc:creator>
<dc:creator>Quin T Waterbury</dc:creator>
<dc:creator>Bryana Belin</dc:creator>
<dc:creator>Jonathan LaBella</dc:creator>
<dc:creator>Leah B Zamechek</dc:creator>
<dc:creator>Melissa H Wong</dc:creator>
<dc:creator>Linheng Li</dc:creator>
<dc:creator>Chandan Guha</dc:creator>
<dc:creator>Chia-Wei Cheng</dc:creator>
<dc:creator>Kelley S Yan</dc:creator>
<dc:creator>Andrea Califano</dc:creator>
<dc:creator>Timothy C Wang</dc:creator>
<dc:date>2024-06-07</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Isthmus progenitor cells contribute to homeostatic cellular turnover and support regeneration following intestinal injury</dc:title>
<dc:identifier>pmid:38848678</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.05.004</dc:identifier>
</item>
<item>
<title>Time-resolved fate mapping identifies the intestinal upper crypt zone as an origin of Lgr5+ crypt base columnar cells</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38848677/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240608121202&amp;v=2.18.0.post9+e462414
      <description>In the prevailing model, Lgr5+ cells are the only intestinal stem cells (ISCs) that sustain homeostatic epithelial regeneration by upward migration of progeny through elusive upper crypt transit-amplifying (TA) intermediates. Here, we identify a proliferative upper crypt population marked by Fgfbp1, in the location of putative TA cells, that is transcriptionally distinct from Lgr5+ cells. Using a kinetic reporter for time-resolved fate mapping and Fgfbp1-CreER^(T2) lineage tracing, we establish...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jun 6;187(12):3039-3055.e14. doi: 10.1016/j.cell.2024.05.001.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">In the prevailing model, Lgr5+ cells are the only intestinal stem cells (ISCs) that sustain homeostatic epithelial regeneration by upward migration of progeny through elusive upper crypt transit-amplifying (TA) intermediates. Here, we identify a proliferative upper crypt population marked by Fgfbp1, in the location of putative TA cells, that is transcriptionally distinct from Lgr5+ cells. Using a kinetic reporter for time-resolved fate mapping and Fgfbp1-CreER<sup>T2</sup> lineage tracing, we establish that Fgfbp1+ cells are multi-potent and give rise to Lgr5+ cells, consistent with their ISC function. Fgfbp1+ cells also sustain epithelial regeneration following Lgr5+ cell depletion. We demonstrate that FGFBP1, produced by the upper crypt cells, is an essential factor for crypt proliferation and epithelial homeostasis. Our findings support a model in which tissue regeneration originates from upper crypt Fgfbp1+ cells that generate progeny propagating bi-directionally along the crypt-villus axis and serve as a source of Lgr5+ cells in the crypt base.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38848677/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240608121202&v=2.18.0.post9+e462414">38848677</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.05.001>10.1016/j.cell.2024.05.001</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38848677</guid>
<pubDate>Fri, 07 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Claudia Capdevila</dc:creator>
<dc:creator>Jonathan Miller</dc:creator>
<dc:creator>Liang Cheng</dc:creator>
<dc:creator>Adam Kornberg</dc:creator>
<dc:creator>Joel J George</dc:creator>
<dc:creator>Hyeonjeong Lee</dc:creator>
<dc:creator>Theo Botella</dc:creator>
<dc:creator>Christine S Moon</dc:creator>
<dc:creator>John W Murray</dc:creator>
<dc:creator>Stephanie Lam</dc:creator>
<dc:creator>Ruben I Calderon</dc:creator>
<dc:creator>Ermanno Malagola</dc:creator>
<dc:creator>Gary Whelan</dc:creator>
<dc:creator>Chyuan-Sheng Lin</dc:creator>
<dc:creator>Arnold Han</dc:creator>
<dc:creator>Timothy C Wang</dc:creator>
<dc:creator>Peter A Sims</dc:creator>
<dc:creator>Kelley S Yan</dc:creator>
<dc:date>2024-06-07</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Time-resolved fate mapping identifies the intestinal upper crypt zone as an origin of Lgr5+ crypt base columnar cells</dc:title>
<dc:identifier>pmid:38848677</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.05.001</dc:identifier>
</item>
<item>
<title>A developmental constraint model of cancer cell states and tumor heterogeneity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38848676/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240608121202&amp;v=2.18.0.post9+e462414
      <description>Cancer is a disease that stems from a fundamental liability inherent to multicellular life forms in which an individual cell is capable of reneging on the interests of the collective organism. Although cancer is commonly described as an evolutionary process, a less appreciated aspect of tumorigenesis may be the constraints imposed by the organism's developmental programs. Recent work from single-cell transcriptomic analyses across a range of cancer types has revealed the recurrence, plasticity,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jun 6;187(12):2907-2918. doi: 10.1016/j.cell.2024.04.032.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cancer is a disease that stems from a fundamental liability inherent to multicellular life forms in which an individual cell is capable of reneging on the interests of the collective organism. Although cancer is commonly described as an evolutionary process, a less appreciated aspect of tumorigenesis may be the constraints imposed by the organism's developmental programs. Recent work from single-cell transcriptomic analyses across a range of cancer types has revealed the recurrence, plasticity, and co-option of distinct cellular states among cancer cell populations. Here, we note that across diverse cancer types, the observed cell states are proximate within the developmental hierarchy of the cell of origin. We thus posit a model by which cancer cell states are directly constrained by the organism's "developmental map." According to this model, a population of cancer cells traverses the developmental map, thereby generating a heterogeneous set of states whose interactions underpin emergent tumor behavior.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38848676/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240608121202&v=2.18.0.post9+e462414">38848676</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.04.032>10.1016/j.cell.2024.04.032</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38848676</guid>
<pubDate>Fri, 07 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Ayushi S Patel</dc:creator>
<dc:creator>Itai Yanai</dc:creator>
<dc:date>2024-06-07</dc:date>
<dc:source>Cell</dc:source>
<dc:title>A developmental constraint model of cancer cell states and tumor heterogeneity</dc:title>
<dc:identifier>pmid:38848676</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.04.032</dc:identifier>
</item>
<item>
<title>A simple rule for predicting function of microbial communities</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38848675/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240608121202&amp;v=2.18.0.post9+e462414
      <description>Microbial communities perform many important functions, such as carbon sequestration, decomposition, pathogen resistance, etc., but quantitatively predicting functions of new communities remains a major challenge. In this issue of Cell, Diaz-Colunga et al. report a new simple statistical regularity that enables such predictions.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jun 6;187(12):2905-2906. doi: 10.1016/j.cell.2024.04.024.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Microbial communities perform many important functions, such as carbon sequestration, decomposition, pathogen resistance, etc., but quantitatively predicting functions of new communities remains a major challenge. In this issue of Cell, Diaz-Colunga et al. report a new simple statistical regularity that enables such predictions.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38848675/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240608121202&v=2.18.0.post9+e462414">38848675</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.04.024>10.1016/j.cell.2024.04.024</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38848675</guid>
<pubDate>Fri, 07 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Sergey Kryazhimskiy</dc:creator>
<dc:date>2024-06-07</dc:date>
<dc:source>Cell</dc:source>
<dc:title>A simple rule for predicting function of microbial communities</dc:title>
<dc:identifier>pmid:38848675</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.04.024</dc:identifier>
</item>
<item>
<title>Unveiling of a messenger: Gut microbes make a neuroactive signal</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38848674/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240608121202&amp;v=2.18.0.post9+e462414
      <description>Gut microbes are known to impact host physiology in several ways. However, key molecular players in host-commensal interactions remain to be uncovered. In this issue of Cell, McCurry et al. reveal that gut bacteria perform 21-dehydroxylation to convert abundant biliary corticoids to neurosteroids using readily available H(2) in their environment.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jun 6;187(12):2903-2904. doi: 10.1016/j.cell.2024.05.014.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Gut microbes are known to impact host physiology in several ways. However, key molecular players in host-commensal interactions remain to be uncovered. In this issue of Cell, McCurry et al. reveal that gut bacteria perform 21-dehydroxylation to convert abundant biliary corticoids to neurosteroids using readily available H<sub>2</sub> in their environment.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38848674/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240608121202&v=2.18.0.post9+e462414">38848674</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.05.014>10.1016/j.cell.2024.05.014</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38848674</guid>
<pubDate>Fri, 07 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Poulami Chatterjee</dc:creator>
<dc:creator>Laura M K Dassama</dc:creator>
<dc:date>2024-06-07</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Unveiling of a messenger: Gut microbes make a neuroactive signal</dc:title>
<dc:identifier>pmid:38848674</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.05.014</dc:identifier>
</item>
<item>
<title>Redefining intestinal stemness: The emergence of a new ISC population</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38848673/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240608121202&amp;v=2.18.0.post9+e462414
      <description>In tissue homeostasis, intestinal stem cells (ISCs) undergo continuous self-renewal to sustain rapid cellular turnover. In this issue of Cell, Capdevila et al.¹ and Malagola, Vasciaveo, et al.² identify a new ISC population in the upper crypt that can generate Lgr5^(+) stem cells during homeostasis.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jun 6;187(12):2900-2902. doi: 10.1016/j.cell.2024.04.021.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">In tissue homeostasis, intestinal stem cells (ISCs) undergo continuous self-renewal to sustain rapid cellular turnover. In this issue of Cell, Capdevila et al.<sup>1</sup> and Malagola, Vasciaveo, et al.<sup>2</sup> identify a new ISC population in the upper crypt that can generate Lgr5<sup>+</sup> stem cells during homeostasis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38848673/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240608121202&v=2.18.0.post9+e462414">38848673</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.04.021>10.1016/j.cell.2024.04.021</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38848673</guid>
<pubDate>Fri, 07 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Mei-Lan Li</dc:creator>
<dc:creator>Kaelyn Sumigray</dc:creator>
<dc:date>2024-06-07</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Redefining intestinal stemness: The emergence of a new ISC population</dc:title>
<dc:identifier>pmid:38848673</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.04.021</dc:identifier>
</item>
<item>
<title>On mechanical phase and form</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38848672/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240608121202&amp;v=2.18.0.post9+e462414
      <description>Epithelial folding is a fundamental biological process that requires epithelial interactions with the underlying mesenchyme. In this issue of Cell, Huycke et al. investigate intestinal villus formation. They discover that water-droplet-like behavior of mesenchymal cells drives their coalescence into uniformly patterned aggregates, which generate forces on the epithelium to initiate folding.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jun 6;187(12):2898-2900. doi: 10.1016/j.cell.2024.04.045.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Epithelial folding is a fundamental biological process that requires epithelial interactions with the underlying mesenchyme. In this issue of Cell, Huycke et al. investigate intestinal villus formation. They discover that water-droplet-like behavior of mesenchymal cells drives their coalescence into uniformly patterned aggregates, which generate forces on the epithelium to initiate folding.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38848672/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240608121202&v=2.18.0.post9+e462414">38848672</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.04.045>10.1016/j.cell.2024.04.045</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38848672</guid>
<pubDate>Fri, 07 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Windie Höfs</dc:creator>
<dc:creator>Sara A Wickström</dc:creator>
<dc:date>2024-06-07</dc:date>
<dc:source>Cell</dc:source>
<dc:title>On mechanical phase and form</dc:title>
<dc:identifier>pmid:38848672</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.04.045</dc:identifier>
</item>
<item>
<title>Resmetirom for treatment of MASH</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38848671/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240608121202&amp;v=2.18.0.post9+e462414
      <description>Resmetirom is an oral selective THR-β agonist conditionally approved for the treatment of patients with noncirrhotic MASH with moderate to advanced fibrosis. Resmetirom restores mitochondrial and hepatic metabolic function; reduces atherogenic lipids; improves hepatic steatosis, inflammation, and fibrosis; and has no significant effect on THR-α. To view this Bench to Bedside, open or download the PDF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jun 6;187(12):2897-2897.e1. doi: 10.1016/j.cell.2024.05.009.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Resmetirom is an oral selective THR-β agonist conditionally approved for the treatment of patients with noncirrhotic MASH with moderate to advanced fibrosis. Resmetirom restores mitochondrial and hepatic metabolic function; reduces atherogenic lipids; improves hepatic steatosis, inflammation, and fibrosis; and has no significant effect on THR-α. To view this Bench to Bedside, open or download the PDF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38848671/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240608121202&v=2.18.0.post9+e462414">38848671</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.05.009>10.1016/j.cell.2024.05.009</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38848671</guid>
<pubDate>Fri, 07 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Silvia Sookoian</dc:creator>
<dc:creator>Carlos Jose Pirola</dc:creator>
<dc:date>2024-06-07</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Resmetirom for treatment of MASH</dc:title>
<dc:identifier>pmid:38848671</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.05.009</dc:identifier>
</item>
<item>
<title>Alcoholic cardiomyopathy: an update</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38848133/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240608121202&amp;v=2.18.0.post9+e462414
      <description>Alcohol-induced cardiomyopathy (AC) is an acquired form of dilated cardiomyopathy (DCM) caused by prolonged and heavy alcohol intake in the absence of other causes. The amount of alcohol required to produce AC is generally considered as >;80 g/day over 5 years, but there is still some controversy regarding this definition. This review on AC focuses on pathogenesis, which involves different mechanisms. Firstly, the direct toxic effect of ethanol promotes oxidative stress in the myocardium and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 7:ehae362. doi: 10.1093/eurheartj/ehae362. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Alcohol-induced cardiomyopathy (AC) is an acquired form of dilated cardiomyopathy (DCM) caused by prolonged and heavy alcohol intake in the absence of other causes. The amount of alcohol required to produce AC is generally considered as >;80 g/day over 5 years, but there is still some controversy regarding this definition. This review on AC focuses on pathogenesis, which involves different mechanisms. Firstly, the direct toxic effect of ethanol promotes oxidative stress in the myocardium and activation of the renin-angiotensin system. Moreover, acetaldehyde, the best-studied metabolite of alcohol, can contribute to myocardial damage impairing actin-myosin interaction and producing mitochondrial dysfunction. Genetic factors are also involved in the pathogenesis of AC, with DCM-causing genetic variants in patients with AC, especially titin-truncating variants. These findings support a double-hit hypothesis in AC, combining genetics and environmental factors. The synergistic effect of alcohol with concomitant conditions such as hypertension or liver cirrhosis can be another contributing factor leading to AC. There are no specific cardiac signs and symptoms in AC as compared with other forms of DCM. However, natural history of AC differs from DCM and relies directly on alcohol withdrawal, as left ventricular ejection fraction recovery in abstainers is associated with an excellent prognosis. Thus, abstinence from alcohol is the most crucial step in treating AC, and specific therapies are available for this purpose. Otherwise, AC should be treated according to current guidelines of heart failure with reduced ejection fraction. Targeted therapies based on AC pathogenesis are currently being developed and could potentially improve AC treatment in the future.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38848133/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240608121202&v=2.18.0.post9+e462414">38848133</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae362>10.1093/eurheartj/ehae362</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38848133</guid>
<pubDate>Fri, 07 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Fernando Domínguez</dc:creator>
<dc:creator>Eric Adler</dc:creator>
<dc:creator>Pablo García-Pavía</dc:creator>
<dc:date>2024-06-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Alcoholic cardiomyopathy: an update</dc:title>
<dc:identifier>pmid:38848133</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae362</dc:identifier>
</item>
<item>
<title>Atrial fibrillation and long-term cardiovascular outcomes: bringing the whole picture into focus</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38848112/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240608121202&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 7:ehae347. doi: 10.1093/eurheartj/ehae347. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38848112/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240608121202&v=2.18.0.post9+e462414">38848112</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae347>10.1093/eurheartj/ehae347</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38848112</guid>
<pubDate>Fri, 07 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Benjamin A Steinberg</dc:creator>
<dc:date>2024-06-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Atrial fibrillation and long-term cardiovascular outcomes: bringing the whole picture into focus</dc:title>
<dc:identifier>pmid:38848112</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae347</dc:identifier>
</item>
<item>
<title>Improving clinical outcomes for patients with coronary artery disease despite no standard modifiable cardiovascular risk factors (SMuRF): not out of the woods yet</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38848109/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240608121202&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 7:ehae271. doi: 10.1093/eurheartj/ehae271. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38848109/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240608121202&v=2.18.0.post9+e462414">38848109</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae271>10.1093/eurheartj/ehae271</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38848109</guid>
<pubDate>Fri, 07 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Gemma A Figtree</dc:creator>
<dc:creator>Michael P Gray</dc:creator>
<dc:date>2024-06-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Improving clinical outcomes for patients with coronary artery disease despite no standard modifiable cardiovascular risk factors (SMuRF): not out of the woods yet</dc:title>
<dc:identifier>pmid:38848109</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae271</dc:identifier>
</item>
<item>
<title>Non-ST-elevation acute coronary syndromes with previous coronary artery bypass grafting: is a routine invasive strategy needed?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38848108/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240608121202&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 7:ehae287. doi: 10.1093/eurheartj/ehae287. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38848108/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240608121202&v=2.18.0.post9+e462414">38848108</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae287>10.1093/eurheartj/ehae287</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38848108</guid>
<pubDate>Fri, 07 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Frans J Beerkens</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:date>2024-06-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Non-ST-elevation acute coronary syndromes with previous coronary artery bypass grafting: is a routine invasive strategy needed?</dc:title>
<dc:identifier>pmid:38848108</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae287</dc:identifier>
</item>
<item>
<title>Polygenic risk score adds to a clinical risk score in the prediction of cardiovascular disease in a clinical setting</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38848106/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240608121202&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In a clinical setting, the addition of genetic information to clinical risk assessment significantly improved the identification of individuals who went on to have a major CVD event as being at high risk, especially among younger individuals. The findings provide important real-world evidence of the potential value of implementing a CVD-PRS into health systems.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 7:ehae342. doi: 10.1093/eurheartj/ehae342. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: A cardiovascular disease polygenic risk score (CVD-PRS) can stratify individuals into different categories of cardiovascular risk, but whether the addition of a CVD-PRS to clinical risk scores improves the identification of individuals at increased risk in a real-world clinical setting is unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The Genetics and the Vascular Health Check Study (GENVASC) was embedded within the UK National Health Service Health Check (NHSHC) programme which invites individuals between 40-74 years of age without known CVD to attend an assessment in a UK general practice where CVD risk factors are measured and a CVD risk score (QRISK2) is calculated. Between 2012-2020, 44,141 individuals (55.7% females, 15.8% non-white) who attended an NHSHC in 147 participating practices across two counties in England were recruited and followed. When 195 individuals (cases) had suffered a major CVD event (CVD death, myocardial infarction or acute coronary syndrome, coronary revascularisation, stroke), 396 propensity-matched controls with a similar risk profile were identified, and a nested case-control genetic study undertaken to see if the addition of a CVD-PRS to QRISK2 in the form of an integrated risk tool (IRT) combined with QRISK2 would have identified more individuals at the time of their NHSHC as at high risk (QRISK2 10-year CVD risk of ≥10%), compared with QRISK2 alone.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The distribution of the standardised CVD-PRS was significantly different in cases compared with controls (cases mean score .32; controls, -.18, P = 8.28×10-9). QRISK2 identified 61.5% (95% confidence interval [CI]: 54.3%-68.4%) of individuals who subsequently developed a major CVD event as being at high risk at their NHSHC, while the combination of QRISK2 and IRT identified 68.7% (95% CI: 61.7%-75.2%), a relative increase of 11.7% (P = 1×10-4). The odds ratio (OR) of being up-classified was 2.41 (95% CI: 1.03-5.64, P = .031) for cases compared with controls. In individuals aged 40-54 years, QRISK2 identified 26.0% (95% CI: 16.5%-37.6%) of those who developed a major CVD event, while the combination of QRISK2 and IRT identified 38.4% (95% CI: 27.2%-50.5%), indicating a stronger relative increase of 47.7% in the younger age group (P = .001). The combination of QRISK2 and IRT increased the proportion of additional cases identified similarly in women as in men, and in non-white ethnicities compared with white ethnicity. The findings were similar when the CVD-PRS was added to the atherosclerotic cardiovascular disease pooled cohort equations (ASCVD-PCE) or SCORE2 clinical scores.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In a clinical setting, the addition of genetic information to clinical risk assessment significantly improved the identification of individuals who went on to have a major CVD event as being at high risk, especially among younger individuals. The findings provide important real-world evidence of the potential value of implementing a CVD-PRS into health systems.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38848106/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240608121202&v=2.18.0.post9+e462414">38848106</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae342>10.1093/eurheartj/ehae342</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38848106</guid>
<pubDate>Fri, 07 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Nilesh J Samani</dc:creator>
<dc:creator>Emma Beeston</dc:creator>
<dc:creator>Chris Greengrass</dc:creator>
<dc:creator>Fernando Riveros-McKay</dc:creator>
<dc:creator>Radoslaw Debiec</dc:creator>
<dc:creator>Daniel Lawday</dc:creator>
<dc:creator>Qingning Wang</dc:creator>
<dc:creator>Charley A Budgeon</dc:creator>
<dc:creator>Peter S Braund</dc:creator>
<dc:creator>Richard Bramley</dc:creator>
<dc:creator>Shireen Kharodia</dc:creator>
<dc:creator>Michelle Newton</dc:creator>
<dc:creator>Andrea Marshall</dc:creator>
<dc:creator>Andre Krzeminski</dc:creator>
<dc:creator>Azhar Zafar</dc:creator>
<dc:creator>Anuj Chahal</dc:creator>
<dc:creator>Amadeeep Heer</dc:creator>
<dc:creator>Kamlesh Khunti</dc:creator>
<dc:creator>Nitin Joshi</dc:creator>
<dc:creator>Mayur Lakhani</dc:creator>
<dc:creator>Azhar Farooqi</dc:creator>
<dc:creator>Vincent Plagnol</dc:creator>
<dc:creator>Peter Donnelly</dc:creator>
<dc:creator>Michael E Weale</dc:creator>
<dc:creator>Christopher P Nelson</dc:creator>
<dc:date>2024-06-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Polygenic risk score adds to a clinical risk score in the prediction of cardiovascular disease in a clinical setting</dc:title>
<dc:identifier>pmid:38848106</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae342</dc:identifier>
</item>
<item>
<title>Fractional flow reserve or optical coherence tomography for angiographically intermediate coronary stenoses: 5-year outcomes in the FORZA trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38848104/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240608121202&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 7:ehae290. doi: 10.1093/eurheartj/ehae290. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38848104/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240608121202&v=2.18.0.post9+e462414">38848104</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae290>10.1093/eurheartj/ehae290</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38848104</guid>
<pubDate>Fri, 07 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Francesco Burzotta</dc:creator>
<dc:creator>Andrea Zito</dc:creator>
<dc:creator>Cristina Aurigemma</dc:creator>
<dc:creator>Enrico Romagnoli</dc:creator>
<dc:creator>Francesco Bianchini</dc:creator>
<dc:creator>Emiliano Bianchini</dc:creator>
<dc:creator>Lazzaro Paraggio</dc:creator>
<dc:creator>Carolina Ierardi</dc:creator>
<dc:creator>Filippo Crea</dc:creator>
<dc:creator>Antonio Maria Leone</dc:creator>
<dc:creator>Carlo Trani</dc:creator>
<dc:date>2024-06-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Fractional flow reserve or optical coherence tomography for angiographically intermediate coronary stenoses: 5-year outcomes in the FORZA trial</dc:title>
<dc:identifier>pmid:38848104</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae290</dc:identifier>
</item>
<item>
<title>The Artificial Intelligence Act approved by the EU: the difficult dialogue between the black box and the cardiologist</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38848102/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240608121202&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 7:ehae281. doi: 10.1093/eurheartj/ehae281. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38848102/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240608121202&v=2.18.0.post9+e462414">38848102</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae281>10.1093/eurheartj/ehae281</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38848102</guid>
<pubDate>Fri, 07 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Piotr Szymański</dc:creator>
<dc:creator>Frank Rademakers</dc:creator>
<dc:creator>Alan G Fraser</dc:creator>
<dc:date>2024-06-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The Artificial Intelligence Act approved by the EU: the difficult dialogue between the black box and the cardiologist</dc:title>
<dc:identifier>pmid:38848102</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae281</dc:identifier>
</item>
<item>
<title>Weekly Journal Scan: Drug-coated balloon for the treatment of in-stent restenosis - the AGENT IDE trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38848101/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240608121202&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 7:ehae305. doi: 10.1093/eurheartj/ehae305. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38848101/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240608121202&v=2.18.0.post9+e462414">38848101</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae305>10.1093/eurheartj/ehae305</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38848101</guid>
<pubDate>Fri, 07 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Daniela Pedicino</dc:creator>
<dc:creator>Rocco Vergallo</dc:creator>
<dc:date>2024-06-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly Journal Scan: Drug-coated balloon for the treatment of in-stent restenosis - the AGENT IDE trial</dc:title>
<dc:identifier>pmid:38848101</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae305</dc:identifier>
</item>
<item>
<title>Cancer begets atrial fibrillation … and vice versa?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38848100/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240608121202&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 7:ehae301. doi: 10.1093/eurheartj/ehae301. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38848100/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240608121202&v=2.18.0.post9+e462414">38848100</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae301>10.1093/eurheartj/ehae301</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38848100</guid>
<pubDate>Fri, 07 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Dimitrios Farmakis</dc:creator>
<dc:creator>Gerasimos Filippatos</dc:creator>
<dc:date>2024-06-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Cancer begets atrial fibrillation … and vice versa?</dc:title>
<dc:identifier>pmid:38848100</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae301</dc:identifier>
</item>
<item>
<title>Office measurement vs. ambulatory blood pressure monitoring: associations with mortality in patients with or without diabetes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38847237/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240608121202&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Diabetes increased the risk for all-cause death, CV, and non-CV death at every level of office and ambulatory BP. Masked and sustained hypertension confer to the highest risk, while white-coat hypertension appears grossly neutral without interaction of relative risk between diabetes and no diabetes. These results support recommendations of international guidelines for strict BP control and using ABPM for classification and assessment of risk and control of hypertension, particularly...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 7:ehae337. doi: 10.1093/eurheartj/ehae337. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Guidelines suggest similar blood pressure (BP) targets in patients with and without diabetes and recommend ambulatory BP monitoring (ABPM) to diagnose and classify hypertension. It was explored whether different levels of ambulatory and office BP and different hypertension phenotypes associate with differences of risk in diabetes and no diabetes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This analysis assessed outcome data from the Spanish ABPM Registry in 59 124 patients with complete available data. The associations between office, mean, daytime, and nighttime ambulatory BP with the risk in patients with or without diabetes were explored. The effects of diabetes on mortality in different hypertension phenotypes, i.e. sustained hypertension, white-coat hypertension, and masked hypertension, compared with normotension were studied. Analyses were done with Cox regression analyses and adjusted for demographic and clinical confounders.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 59 124 patients were recruited from 223 primary care centres in Spain. The majority had an office systolic BP >;140 mmHg (36 700 patients), and 23 128 (40.6%) patients were untreated. Diabetes was diagnosed in 11 391 patients (19.2%). Concomitant cardiovascular (CV) disease was present in 2521 patients (23.1%) with diabetes and 4616 (10.0%) without diabetes. Twenty-four-hour mean, daytime, and nighttime ambulatory BP were associated with increased risk in diabetes and no diabetes, while in office BP, there was no clear association with no differences with and without diabetes. While the relative association of BP to CV death risk was similar in diabetes compared with no diabetes (mean interaction P = .80, daytime interaction P = .97, and nighttime interaction P = .32), increased event rates occurred in diabetes for all ABPM parameters for CV death and all-cause death. White-coat hypertension was not associated with risk for CV death (hazard ratio 0.86; 95% confidence interval 0.72-1.03) and slightly reduced risk for all-cause death in no diabetes (hazard ratio 0.89; confidence interval 0.81-0.98) but without significant interaction between diabetes and no diabetes. Sustained hypertension and masked hypertension in diabetes and no diabetes were associated with even higher risk. There were no significant interactions in hypertensive phenotypes between diabetes and no diabetes and CV death risk (interaction P = .26), while some interaction was present for all-cause death (interaction P = .043) and non-CV death (interaction P = .053).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Diabetes increased the risk for all-cause death, CV, and non-CV death at every level of office and ambulatory BP. Masked and sustained hypertension confer to the highest risk, while white-coat hypertension appears grossly neutral without interaction of relative risk between diabetes and no diabetes. These results support recommendations of international guidelines for strict BP control and using ABPM for classification and assessment of risk and control of hypertension, particularly in patients with diabetes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CLINICAL TRIAL REGISTRATION: Not applicable.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38847237/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240608121202&v=2.18.0.post9+e462414">38847237</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae337>10.1093/eurheartj/ehae337</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38847237</guid>
<pubDate>Fri, 07 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Michael Böhm</dc:creator>
<dc:creator>Alejandro de la Sierra</dc:creator>
<dc:creator>Felix Mahfoud</dc:creator>
<dc:creator>Igor Schwantke</dc:creator>
<dc:creator>Lucas Lauder</dc:creator>
<dc:creator>Bernhard Haring</dc:creator>
<dc:creator>Ernest Vinyoles</dc:creator>
<dc:creator>Manuel Gorostidi</dc:creator>
<dc:creator>Julián Segura</dc:creator>
<dc:creator>Bryan Williams</dc:creator>
<dc:creator>Natalie Staplin</dc:creator>
<dc:creator>Luis M Ruilope</dc:creator>
<dc:date>2024-06-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Office measurement vs. ambulatory blood pressure monitoring: associations with mortality in patients with or without diabetes</dc:title>
<dc:identifier>pmid:38847237</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae337</dc:identifier>
</item>
<item>
<title>Tipifarnib Reduces Extracellular Vesicles and Protects From Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38847080/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240608121202&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our study underscores the pathological role of exosomes in HF and fibrosis in response to pressure overload. Tipifarnib-mediated inhibition of exosome biogenesis and cargo sorting may serve as a viable strategy to prevent progressive cardiac remodeling in HF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jun 7. doi: 10.1161/CIRCRESAHA.123.324110. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Heart failure (HF) is one of the leading causes of mortality worldwide. Extracellular vesicles, including small extracellular vesicles or exosomes, and their molecular cargo are known to modulate cell-to-cell communication during multiple cardiac diseases. However, the role of systemic extracellular vesicle biogenesis inhibition in HF models is not well documented and remains unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We investigated the role of circulating exosomes during cardiac dysfunction and remodeling in a mouse transverse aortic constriction (TAC) model of HF. Importantly, we investigate the efficacy of tipifarnib, a recently identified exosome biogenesis inhibitor that targets the critical proteins (Rab27a, nSMase2 [neutral sphingomyelinase 2], and Alix [ALG-2-interacting protein X]) involved in exosome biogenesis for this mouse model of HF. In this study, 10-week-old male mice underwent TAC surgery were randomly assigned to groups with and without tipifarnib treatment (10 mg/kg 3 times/wk) and monitored for 8 weeks, and a comprehensive assessment was conducted through performed echocardiographic, histological, and biochemical studies.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: TAC significantly elevated circulating plasma exosomes and markedly increased cardiac left ventricular dysfunction, cardiac hypertrophy, and fibrosis. Furthermore, injection of plasma exosomes from TAC mice induced left ventricular dysfunction and cardiomyocyte hypertrophy in uninjured mice without TAC. On the contrary, treatment of tipifarnib in TAC mice reduced circulating exosomes to baseline and remarkably improved left ventricular functions, hypertrophy, and fibrosis. Tipifarnib treatment also drastically altered the miRNA profile of circulating post-TAC exosomes, including miR 331-5p, which was highly downregulated both in TAC circulating exosomes and in TAC cardiac tissue. Mechanistically, miR 331-5p is crucial for inhibiting the fibroblast-to-myofibroblast transition by targeting HOXC8, a critical regulator of fibrosis. Tipifarnib treatment in TAC mice upregulated the expression of miR 331-5p that acts as a potent repressor for one of the fibrotic mechanisms mediated by HOXC8.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our study underscores the pathological role of exosomes in HF and fibrosis in response to pressure overload. Tipifarnib-mediated inhibition of exosome biogenesis and cargo sorting may serve as a viable strategy to prevent progressive cardiac remodeling in HF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38847080/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240608121202&v=2.18.0.post9+e462414">38847080</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.324110>10.1161/CIRCRESAHA.123.324110</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38847080</guid>
<pubDate>Fri, 07 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Vandana Mallaredy</dc:creator>
<dc:creator>Rajika Roy</dc:creator>
<dc:creator>Zhongjian Cheng</dc:creator>
<dc:creator>Charan Thej Gurrala</dc:creator>
<dc:creator>Cindy Benedict</dc:creator>
<dc:creator>May Truongcao</dc:creator>
<dc:creator>Darukeshwara Joladarashi</dc:creator>
<dc:creator>Ajit Magadum</dc:creator>
<dc:creator>Jessica Ibetti</dc:creator>
<dc:creator>Maria Cimini</dc:creator>
<dc:creator>Carolina Gonzalez</dc:creator>
<dc:creator>Venkata Naga Srikanth Garikipati</dc:creator>
<dc:creator>Walter J Koch</dc:creator>
<dc:creator>Raj Kishore</dc:creator>
<dc:date>2024-06-07</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Tipifarnib Reduces Extracellular Vesicles and Protects From Heart Failure</dc:title>
<dc:identifier>pmid:38847080</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.324110</dc:identifier>
</item>
<item>
<title>Loop diuretic utilisation with or without heart failure: impact on prognosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38845446/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240608121202&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: For patients with cardiovascular disease, many are prescribed loop diuretics without a diagnosis of heart failure being recorded. Mortality is more strongly associated with loop diuretic use than with a heart failure record. The diagnosis of heart failure may be often missed, or loop diuretic use is associated with other conditions with a prognosis similar to heart failure, or inappropriate loop diuretic use increases mortality; all might be true.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 7:ehae345. doi: 10.1093/eurheartj/ehae345. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND & AIMS: Many patients are prescribed loop diuretics without a diagnostic record of heart failure. Little is known about their characteristics and prognosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Glasgow regional health records (2009-2016) were obtained for adults with cardiovascular disease or taking loop diuretics. Outcomes were investigated using Cox models with hazard ratios adjusted for age, sex, socioeconomic deprivation, and co-morbid disease (adjHR).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 198,898 patients (median age 65 years; 55% women), 161,935 (81%) neither took loop diuretics nor had a diagnostic record of heart failure (reference group), 23,963 (12%) were taking loop diuretics but had no heart failure recorded, 7,844 (4%) had heart failure recorded and took loop diuretics and 5,156 (3%) had heart failure recorded but were not receiving loop diuretics.Five-year mortality was only slightly higher for heart failure in absence of loop diuretics (22%; adjHR: 1.2 [95% CI 1.1-1.3]), substantially higher for those taking loop diuretics with no heart failure recorded (40%; adjHR: 1.8 [95% CI 1.7-1.8]) and highest for heart failure treated with loop diuretics (52%; adjHR: 2.2 [95% CI 2.0-2.2]).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: For patients with cardiovascular disease, many are prescribed loop diuretics without a diagnosis of heart failure being recorded. Mortality is more strongly associated with loop diuretic use than with a heart failure record. The diagnosis of heart failure may be often missed, or loop diuretic use is associated with other conditions with a prognosis similar to heart failure, or inappropriate loop diuretic use increases mortality; all might be true.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38845446/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240608121202&v=2.18.0.post9+e462414">38845446</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae345>10.1093/eurheartj/ehae345</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38845446</guid>
<pubDate>Fri, 07 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Jocelyn M Friday</dc:creator>
<dc:creator>John Gf Cleland</dc:creator>
<dc:creator>Pierpaolo Pellicori</dc:creator>
<dc:creator>Maria Wolters</dc:creator>
<dc:creator>John Jv McMurray</dc:creator>
<dc:creator>Pardeep S Jhund</dc:creator>
<dc:creator>Paul Forsyth</dc:creator>
<dc:creator>David A McAllister</dc:creator>
<dc:creator>Fraser J Graham</dc:creator>
<dc:creator>Yola Jones</dc:creator>
<dc:creator>Jim Lewsey</dc:creator>
<dc:date>2024-06-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Loop diuretic utilisation with or without heart failure: impact on prognosis</dc:title>
<dc:identifier>pmid:38845446</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae345</dc:identifier>
</item>





























</channel>
</rss>